Vagus Nerve Stimulation (implantable and noninvasive) Coverage Criteria
Customize your policy alerts
Sign up for all fallon_community_health_plan_inc policy alerts
Know when fallon_community_health_plan_inc releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Fallon Health coverage, prior authorization, and medical necessity criteria for implantable vagus nerve stimulation (VNS) and addresses noninvasive/transcutaneous VNS; applies to Fallon Community products listed and notes Medicare/MassHealth variations.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Implantable VNS — Coverage with criteria (InterQual)
Covered when ALL of the following are met:
Effective for dates of service on or after August 1, 2024
Coverage applies only to implantable VNS; noninvasive/transcutaneous VNS is addressed separately
Medicare-specific coverage rules
Medicare variation and nationally covered/noncovered rules:
Refer to Medicare NCD and MAC guidance
Fallon covers routine costs for members participating in CMS‑approved CED studies
Medicare statutes/regulations and the Medicare Benefit Policy Manual govern coverage determinations
Not medically necessary / Experimental
Not medically necessary / Experimental — Not covered when ANY of the following apply:
Evidence-based coverage rationale
Summary of evidence-based determinations and subgroup findings:
Evidence supports use in a subset of eCH patients; overall trial results mixed by subgroup
Study limitations include open‑label design and short duration
When the specific coverage criteria in this policy are not met, implantable vagus nerve stimulation is considered experimental/investigational and not medically necessary. Decisions about medical necessity will reflect the policy requirements and applicable prior authorization determinations; services that do not meet the criteria are subject to denial.
The codes listed in this policy are provided for informational purposes only. Inclusion of a code does not constitute or imply coverage, and code reporting restrictions noted in the policy (for example, do not report CPT 64568 with CPT 61885/61886/64570) must be followed when submitting claims.
Policy history was updated on 07/22/2025 to add an explicit exclusion for integrated vagus nerve neurostimulation systems. The update notes that CPT codes 0908T–0912T were added as excluded (considered experimental/investigational and not medically necessary) without changes to the coverage criteria.
Vagus nerve stimulation is considered not medically necessary for indications beyond the covered criteria. Examples explicitly listed as not medically necessary include treatment of depression, stroke, essential tremor, headaches, fibromyalgia, and traumatic brain injury. Noninvasive/transcutaneous devices (HCPCS E0735) are also designated not medically necessary for all indications in this policy.
The evidence for noninvasive VNS (nVNS, e.g., gammaCore) shows benefit in some patients but is limited and variable. Randomized trials and cohort studies indicate nVNS can be effective for acute treatment in episodic cluster headache and PREVA showed reduced attack frequency when used prophylactically in chronic cluster headache, but study limitations (short duration, open-label design, and variable definitions of rescue medication) and differential responses between episodic and chronic subgroups mean nVNS is not effective in everyone and further research is needed to define optimal patient selection and regimens.
Codes and Billing References
| E0735 | Noninvasive (transcutaneous) vagus nerve stimulation device (as referenced) |
| 0312T | Rechargeable vagal blocking systems (Category III CPT) - sunset Jan 1, 2023 (listed among 0312T-0317T) |
| 0313T | Rechargeable vagal blocking systems (Category III CPT) |
| 0314T | Rechargeable vagal blocking systems (Category III CPT) |
| 0315T | Rechargeable vagal blocking systems (Category III CPT) |
| 0316T | Rechargeable vagal blocking systems (Category III CPT) |
| 0317T | Rechargeable vagal blocking systems (Category III CPT) |
| 0908T | Integrated vagus nerve neurostimulation systems (0908T-0912T) — listed as experimental/investigational |
| 0909T | Integrated vagus nerve neurostimulation systems |
| 0910T | Integrated vagus nerve neurostimulation systems |
| 0911T | Integrated vagus nerve neurostimulation systems |
| 0912T | Integrated vagus nerve neurostimulation systems |
| 64568 | Open implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator. |
| 61885 | Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to a single electrode array. |
| 61886 | Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to 2 or more electrode arrays. |
| 64569 | Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator. |
| 64570 | Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator. |
| 61888 | Revision or removal of cranial neurostimulator pulse generator or receiver. |
| 95970 | Electronic analysis of implanted neurostimulator pulse generator/transmitter without programming. |
| 95976 | Electronic analysis of implanted neurostimulator pulse generator/transmitter with simple programming. |
| 95977 | Electronic analysis of implanted neurostimulator pulse generator/transmitter with complex programming. |
| 95976 | Electronic analysis of implanted neurostimulator pulse generator/transmitter with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional |
| 95977 | Electronic analysis of implanted neurostimulator pulse generator/transmitter with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional |
Provider Requirements, Authorization, and Documentation
Prior authorization required
Prior authorization is required for vagus nerve stimulation for Fallon Health products listed in the policy (including Fallon Medicare Advantage, MassHealth ACO, Community Care, NaviCare plans, PACE).
Coding listed for implantation, revision, removal, programming, and device supplies (informational)
The policy lists procedure, analysis and device supply codes for informational purposes only — including implantation, replacement, revision, removal, programming, and device supply codes. Inclusion of these codes does not constitute or imply coverage.
Code-based authorization guidance — listed CPT and device codes referenced for coverage review
Services and devices identified by the listed CPT and device codes (e.g., 95976, 95977, C1767, C1778, L8680, L8686 and implantation/removal codes) are the items referenced for coverage and billing review; prior authorization and submitted coding will be assessed against policy criteria and applicable Medicare NCDs/LCDs.
- Prior authorization may be required per plan rules; submitted CPT/HCPCS/L-codes will be reviewed against policy and any applicable Medicare coverage determinations.
Step therapy — not specified
The policy does not specify any step therapy requirements for vagus nerve stimulation in this portion of the document.
Place in therapy guidance — adjunct to standard care when standard treatments ineffective/intolerant/contraindicated
NICE guidance positions noninvasive transcutaneous VNS (gammaCore) as an adjunct to standard care, most likely where standard treatments are ineffective, not tolerated, or contraindicated.
- NICE notes evidence quantity/quality is limited and recommends further research to clarify optimal patient selection and regimens.
Coverage may vary by product and benefit; consult member Evidence of Coverage
Coverage may vary by product and benefit; providers must consult the member’s Evidence of Coverage or benefit plan because not all services mentioned in the policy are covered for all products or employer groups.
- If a member's benefit plan conflicts with this policy, the benefit plan provisions govern; applicable state or federal mandates may supersede.
Documentation for medical necessity — use InterQual CP:Procedures, Vagus Nerve Stimulation
Medical necessity determinations for implantable vagus nerve stimulation will be made using InterQual® CP: Procedures, Vagus Nerve Stimulation in effect on the date of service.
- InterQual criteria effective for dates of service on or after August 1, 2024 are used for Community Care and MassHealth ACO members.
Study documentation practices — headache diaries, attack timing, pain intensity, cycles, rescue med use, prophylactic regimen recording
Clinical study documentation practices include prospective headache/attack diaries recording timing of attacks, treatment cycles applied, pain intensity, use of rescue medications, and maintenance of prophylactic regimens per study protocols.
- ACT2: subjects recorded all attacks, applied three 120‑second stimulation cycles at onset and documented additional cycles, rescue medication use, and timing between attacks.
- PREVA: prophylactic regimen documented as three 2‑minute stimulations separated by 5 minutes, twice daily, and recording of acute treatments and abortive medication use if attacks persisted beyond 15 minutes.
Check member benefit plan / Evidence of Coverage before ordering
Providers must consult the member’s specific benefit plan/Evidence of Coverage because not all services mentioned in this policy are covered for all products; benefit provisions and applicable mandates govern coverage.
Denial triggers — experimental/investigational or criteria not met
Implantable vagus nerve stimulation is considered experimental/investigational and not medically necessary when the policy’s coverage criteria are not met; noninvasive transcutaneous VNS devices (E0735) are considered experimental/investigational and not medically necessary for all indications per this policy portion.
- Coverage denials may result when device use is outside established indications or when InterQual/Medicare criteria are not satisfied.
Coding inclusion is informational only — inclusion does not imply coverage; reporting exclusions noted
The codes included in the policy are informational only; inclusion does not constitute or imply coverage and the policy specifies reporting exclusions (for example, do not report CPT 64568 with CPT 61885, 61886, or 64570).
Medicare Advantage coverage determinations follow CMS NCDs/LCDs and statutes/regulations
For Medicare Advantage members, Fallon Health follows CMS national and local coverage determinations (NCDs/LCDs) and applicable statutes/regulations when making coverage determinations; failure to meet CMS requirements or to follow NCDs/LCDs may result in denial.
- When Medicare criteria are not fully established, Fallon may create internal coverage criteria only under specified regulatory circumstances.
Background and Rationale
An implantable vagus nerve stimulator consists of an implanted pulse generator and lead placed to stimulate the left vagus nerve; device settings are adjusted with an external programmer. Implantable VNS is FDA‑approved for selected indications (for example, refractory partial‑onset seizures) and coverage in this policy is limited to FDA‑approved implantable systems when the policy criteria are met. Noninvasive (transcutaneous) VNS devices stimulate the cervical branch of the vagus nerve externally (example: gammaCore) and have more limited, indication‑specific evidence and regulatory clearances.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.